Steigerwald, Gordon & Koch Inc. Xeris Biopharma Holdings, Inc. Transaction History
Steigerwald, Gordon & Koch Inc.
- $977 Million
- Q3 2025
A detailed history of Steigerwald, Gordon & Koch Inc. transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Steigerwald, Gordon & Koch Inc. holds 37 shares of XERS stock, worth $341. This represents 0.0% of its overall portfolio holdings.
Number of Shares
37Holding current value
$341% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding XERS
# of Institutions
212Shares Held
90MCall Options Held
81.6KPut Options Held
57.6K-
Black Rock Inc. New York, NY10.3MShares$95.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$90.7 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY3.84MShares$35.4 Million0.01% of portfolio
-
State Street Corp Boston, MA3.78MShares$35 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.65MShares$33.7 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $1.26B
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...